ERBB2 and breast cancer: Previous studies demonstrated that metastatic BC patients overexpressing p95HER2 had considerably lower response rates to trastuzumab compared with patients expressing full-length HER2.[46] In this trial, Scaltriti et al. also evaluated the effect of lapatinib in a p95HER2 preclinical model of p95HER2-positive MCF-7 cells.